Immunodeficiency - top articles for February 2014

Here are my suggestions for some of the top articles about immunodeficiency from the last few months:

Polysaccharide nonresponsiveness in selective antibody deficiency can be classified into 4 phenotypes

B cell chemoattractant chemokine (CXC motif) ligand 13 as CSF marker may help identify neurosyphilis

Use of indwelling ports or central venous lines in antibody deficient patients: contraindicated

Warts and all: A review of human papillomavirus in primary immunodeficiencies

Pharmacoeconomic advantages of subcutaneous versus intravenous immunoglobulin treatment in a Canadian pediatric center: the financial arguments for SC-Ig are appealing with greater expected benefits at less cost. SC-Ig dose is equivalent to IV-Ig dose in Europe/Canada whereas US recommendations lean toward 37% higher dose of SC-Ig

Evaluation of a patient with possible immunodeficiency who does not respond to a pneumococcal vaccine - AAAAI Ask the Expert

Challenges of genetic counseling in patients with autosomal dominant diseases, such as hyper-IgE syndrome (STAT3-HIES)

Classification of primary immunodeficiencies: Need for a revised approach?

The data do not support a role of mannose-binding lectin (MBL) deficiency in pneumococcal infection -- Many individuals with mannose binding lectin (MBL) deficiency do not suffer any adverse symptoms related to low MBL

When to administer immunoglobulin replacement therapy - the decision is not based solely on IgG levels

The use of meningococcal vaccine in patients with common variable immunodeficiency (CVID) - it could work

Screening for primary immunodeficiency should be part of diagnostic workup of refractory chronic rhinosinusitis (CRS)

The articles were selected from Twitter @Allergy and RSS subscriptions. Some of the top allergy accounts on Twitter contributed links. I appreciate the curation provided by @Aller_MD @AllergyNet @IgECPD @DrAnneEllis @AACMaven @AllergieVoeding @allergistmommy @mrathkopf @wheezemd.

Please feel free to send suggestions for articles to allergycases AT gmail DOT com and you will receive an acknowledgement in the next edition of this publication.

No comments:

Post a Comment